Compare DLNG & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLNG | KPTI |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.0M | 148.0M |
| IPO Year | 2013 | 2013 |
| Metric | DLNG | KPTI |
|---|---|---|
| Price | $3.87 | $6.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $22.17 |
| AVG Volume (30 Days) | 54.7K | ★ 413.6K |
| Earning Date | 03-05-2026 | 02-18-2026 |
| Dividend Yield | ★ 5.14% | N/A |
| EPS Growth | ★ 30.14 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $158,275,000.00 | $142,530,000.00 |
| Revenue This Year | N/A | $3.82 |
| Revenue Next Year | $0.37 | N/A |
| P/E Ratio | $3.02 | ★ N/A |
| Revenue Growth | ★ 4.34 | N/A |
| 52 Week Low | $3.18 | $3.51 |
| 52 Week High | $5.35 | $10.80 |
| Indicator | DLNG | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 60.55 | 39.97 |
| Support Level | $3.70 | $7.05 |
| Resistance Level | $4.18 | $8.95 |
| Average True Range (ATR) | 0.13 | 0.62 |
| MACD | 0.01 | -0.18 |
| Stochastic Oscillator | 50.00 | 1.85 |
Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and are winterized which enables trade in subzero and ice bound conditions.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.